Investment firm Admaius Capital from Africa provides financial support to a biopharmaceutical company, marking its eighth bet since the launch of its initial fund
Admaius Capital Partners Invests in Leading African Biopharma Company
Admaius Capital Partners, a pan-Africa-focused private equity firm managing assets worth over $280 million, has made an investment in Minapharm Pharmaceuticals and Chemical Industries (Minapharm), a leading biopharmaceutical company based in Egypt.
Minapharm is recognized as a significant player in the region, with capabilities in developing and manufacturing complex genetically engineered therapeutic recombinant proteins, viral vectors, and advanced biologics. The company operates the largest biological drug substance and product facilities in the Middle East and Africa, with operations spanning Cairo and Berlin. It is also a global provider of proprietary technologies in monoclonal antibodies, vaccines, and cell and gene therapies, many of which are incorporated into FDA-approved products.
Admaius Capital Partners took a minority equity stake in Triquera B.V., the majority shareholder of Minapharm, to support Minapharm’s regional and global expansion. The investment aims to accelerate the development and production of advanced therapies and expand access to high-quality, affordable recombinant proteins across underserved markets in Africa and the Middle East. The partnership also seeks to grow Minapharm's footprint through innovation, strategic acquisitions of global contract development and manufacturing organizations (CDMOs), and scaling distribution to underserved markets.
Existing members can log in to access more details about this investment, which marks the eighth deal from Admaius Capital Partners' inaugural investment vehicle. To access the premium content, one must become a Premium member.
[1] Admaius Capital Partners Press Release, [Link to Press Release] [2] Minapharm Pharmaceuticals and Chemical Industries Website, [Link to Website] [3] Egyptian Medical Syndicate, [Link to Article] [4] Pharmaceutical Technology, [Link to Article]
- Admaius Capital Partners' investment in Minapharm Pharmaceuticals and Chemical Industries, a leading African biopharmaceutical company, is aimed at accelerating the development and production of advanced therapies and expanding access to high-quality, affordable recombinant proteins across underserved markets in Africa and the Middle East.
- The finance from Admaius Capital Partners' investment in Minapharm will be used to grow Minapharm's footprint through innovation, strategic acquisitions of global contract development and manufacturing organizations (CDMOs), and scaling distribution to underserved markets.